X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership is for the development and manufacturing of N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy for the treatment of various cancer indications, including Pancreatic Cancer, Lung Cancer and other solid tumours.
Lead Product(s): Neutrophil Progenitor-based Leukocyte Infusion Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: LIfT Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 16, 2023
Details:
DCP-001 is currently being evaluated in the ADVANCE II Phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON Phase 1 clinical trial in ovarian cancer.
Lead Product(s): DCP-001
Therapeutic Area: Oncology Product Name: DCP-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Recipient: Mendus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 17, 2022
Details:
Minaris will be responsible for the GMP manufacturing, freezing and shipping of the MVX-ONCO-2 capsules, which will be delivered to clinical sites. The autologous patients’ tumor cells will be processed at the clinical sites.
Lead Product(s): MVX-ONCO-2
Therapeutic Area: Oncology Product Name: MVX-ONCO-2
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: MaxiVAX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
